Matches children and young people to leukemia treatment plans
Part of Blood & lymphatic, Cancer clinical trials.
This trial is set up to review tumor lab test results to help doctors choose the most appropriate next treatment for people with leukemia that has returned or did not respond. It mainly matters for younger patients who are not already on a standard treatment path.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have leukemia or another blood cancer that is back or not responding
- You were diagnosed before age 18, and you are under 25 when you join the study
- You are being treated in a pediatric or young adult (AYA) cancer program, with no current standard treatment plan
- Your expected lifetime is at least 6 weeks
- Your tumor has had molecular testing, and the results are available
- Your tumor has had flow cytometry testing in a certified lab, and the results are available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
This trial offers a personalized treatment plan for children with hard-to-treat or relapsed acute myeloid leukemia (AML). The plan is based on the unique genetic makeup of the child's cancer and lab tests that find the most effective drugs.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This trial tests a new cell therapy (BG1805) for children whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The therapy targets a specific marker on leukemia cells called CLL-1 and aims to help the immune system fight the cancer.
Hear when a new Relapsed Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.